On November 24, 2022 Hemispherian AS ("Hemispherian" or the "Company"), a Norwegian preclinical pharmaceutical company focused on small molecule cancer therapeutics targeting the DNA damage response, reported the closure of the first tranche of its series A1 financing round (Press release, Hemispherian, NOV 24, 2022, View Source [SID1234624410]). The round raised NOK 30M (USD 2.9M). The proceeds will support the company’s drug development activities, expand its preclinical pipeline and advance its lead therapeutic compounds towards clinical development.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The round was led by the Dutch Investment Firm, Meneldor, who partnered with Norwegian and American investors. Among the Norwegian investors are Kistefos AS and Kvantia AS. Most of the earlier investors followed their seed investment, and the board chaired by Steven Powell, remains unchanged.